• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Orion Biotech Opportunities Corp.

    12/20/21 4:35:04 PM ET
    $ORIA
    Blank Checks
    Finance
    Get the next $ORIA alert in real time by email
    425 1 ea152569-8k425_orion.htm CURRENT REPORT

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 15, 2021

     

    ORION BIOTECH OPPORTUNITIES CORP.

    (Exact name of registrant as specified in its charter)

     

     

     

    Cayman Islands   001-40410   98-1583924
    (State or other jurisdiction of
    incorporation or organization)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

     

     

    645 Fifth Avenue, 21st Floor
    New York, New York
      10022
    (Address of principal executive offices)   (Zip Code)

     

    (212) 303-1650

    Registrant’s telephone number, including area code

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one Class A ordinary share, $0.0001 par value per share, and one-fifth of one redeemable warrant   ORIAU   The Nasdaq Stock Market LLC
    Class A ordinary shares included as part of the Units   ORIA   The Nasdaq Stock Market LLC
    Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50   ORIAQ   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    This Current Report on Form 8-K is filed by Orion Biotech Opportunities Corp., a Cayman Islands exempted company (the “Company”), in connection with the matters described herein.

     

    Item 4.02 Non-Reliance on Previously Issued Financial Statement and Related Audit Report.

     

    On December 15, 2021, the Company’s management (the “Management”) and the audit committee of the Company’s board of directors (the “Audit Committee”), concluded that due to a reclassification of the Company’s temporary and permanent equity, the Company’s previously issued revision to the (i) unaudited interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed with the SEC on August 12, 2021, and (ii) Note 2 to the unaudited interim financial statements and Item 4 of Part 1 included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the SEC on November 12, 2021 (collectively, the “Affected Periods”), should be restated and should no longer be relied upon. In addition, the audit report of WithumSmith+Brown, PC (“Withum”), the Company’s independent registered public accounting firm, included in the Current Report on Form 8-K filed with the SEC on May 21, 2021 should no longer be relied upon.

     

    Since the Company’s initial public offering (“IPO”), the Company has considered the Class A ordinary shares subject to possible redemption to be equal to the redemption value of $10.00 per Class A ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable stock classified as temporary equity as part of net tangible assets. Upon further analysis, Management has determined that the Class A ordinary shares issued during the IPO and pursuant to the exercise of the underwriters’ overallotment can be redeemed or become redeemable subject to the occurrence of future events considered outside the Company’s control. Therefore, Management concluded that the redemption value should include all Class A ordinary shares subject to possible redemption, resulting in the Class A ordinary shares subject to possible redemption being equal to their redemption value.

     

    The Company does not expect any of the above changes will have any impact on its cash position and investments held in the trust account established in connection with the IPO. The Company’s Management and the Audit Committee have discussed the matters disclosed in this Form 8-K with Withum.

     

    As such, the Company has restated its financial statements for the Affected Periods in the Company’s Q3 Form 10-Q, as described therein.

     

    Cautionary Statements Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company’s cash position and investments held in its trust account. These statements are based on current expectations on the date of this Form 8-K and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

     

    1 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 20, 2021 ORION BIOTECH OPPORTUNITIES CORP.
         
      By: /s/ Mark Kayal
        Name:  Mark Kayal
        Title: Chief Financial Officer

     

     

    2

     

     

    Get the next $ORIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORIA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORIA
    SEC Filings

    View All

    SEC Form 15-12G filed by Orion Biotech Opportunities Corp.

    15-12G - Orion Biotech Opportunities Corp. (0001847416) (Filer)

    5/11/23 8:00:14 AM ET
    $ORIA
    Blank Checks
    Finance

    SEC Form 25 filed by Orion Biotech Opportunities Corp.

    25 - Orion Biotech Opportunities Corp. (0001847416) (Filer)

    5/1/23 4:39:07 PM ET
    $ORIA
    Blank Checks
    Finance

    Orion Biotech Opportunities Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Orion Biotech Opportunities Corp. (0001847416) (Filer)

    4/24/23 4:10:16 PM ET
    $ORIA
    Blank Checks
    Finance

    $ORIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Collins James J.

    4 - Orion Biotech Opportunities Corp. (0001847416) (Issuer)

    5/18/23 4:05:11 PM ET
    $ORIA
    Blank Checks
    Finance

    SEC Form 4 filed by Broder Samuel

    4 - Orion Biotech Opportunities Corp. (0001847416) (Issuer)

    5/18/23 4:05:11 PM ET
    $ORIA
    Blank Checks
    Finance

    SEC Form 4 filed by Orion Sponsor Holdings, Llc

    4 - Orion Biotech Opportunities Corp. (0001847416) (Issuer)

    5/18/23 4:05:13 PM ET
    $ORIA
    Blank Checks
    Finance

    $ORIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Orion Biotech Opportunities Corp. (Amendment)

    SC 13G/A - Orion Biotech Opportunities Corp. (0001847416) (Subject)

    2/14/24 4:01:45 PM ET
    $ORIA
    Blank Checks
    Finance

    SEC Form SC 13G filed by Orion Biotech Opportunities Corp.

    SC 13G - Orion Biotech Opportunities Corp. (0001847416) (Subject)

    2/15/22 8:40:07 AM ET
    $ORIA
    Blank Checks
    Finance

    SEC Form SC 13G filed by Orion Biotech Opportunities Corp.

    SC 13G - Orion Biotech Opportunities Corp. (0001847416) (Subject)

    10/15/21 1:44:03 PM ET
    $ORIA
    Blank Checks
    Finance